IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!)

Citations for "Adjusting the Value of a Statistical Life for Age and Cohort Effects"

by Aldy, Joseph E. & Viscusi, W. Kip

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. Antoine Bommier & Bertrand Villeneuve, 2004. "Risk Aversion and the Value of Risk to Life," CESifo Working Paper Series 1267, CESifo Group Munich.
  2. Hala Abou-Ali & Hesham El-Azony & Heba El-Laithy & Jonathan Haughton & Shahid Khandker, 2010. "Evaluating the impact of Egyptian Social Fund for Development programmes," Journal of Development Effectiveness, Taylor & Francis Journals, vol. 2(4), pages 521-555.
  3. Aldy, Joseph E. & Smyth, Seamus J., 2014. "Heterogeneity in the Value of Life," Working Paper Series rwp14-024, Harvard University, John F. Kennedy School of Government.
  4. Swensen, Isaac D., 2015. "Substance-abuse treatment and mortality," Journal of Public Economics, Elsevier, vol. 122(C), pages 13-30.
  5. Mary F. Evans & V. Kerry Smith, 2008. "Complementarity and the Measurement of Individual Risk Tradeoffs: Accounting for Quantity and Quality of Life Effects," NBER Working Papers 13722, National Bureau of Economic Research, Inc.
  6. Kniesner, Thomas J. & Viscusi, W. Kip & Ziliak, James P., 2009. "Policy Relevant Heterogeneity in the Value of Statistical Life: New Evidence from Panel Data Quantile Regressions," IZA Discussion Papers 4508, Institute for the Study of Labor (IZA).
  7. Clapp, John M. & Eichholtz, Piet & Lindenthal, Thies, 2013. "Real option value over a housing market cycle," Regional Science and Urban Economics, Elsevier, vol. 43(6), pages 862-874.
  8. Cameron, Trudy Ann & DeShazo, J.R., 2013. "Demand for health risk reductions," Journal of Environmental Economics and Management, Elsevier, vol. 65(1), pages 87-109.
  9. Frank R. Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 277-299, July.
  10. Michael Jones-Lee & Susan Chilton & Hugh Metcalf & Jytte Nielsen, 2015. "Valuing gains in life expectancy: Clarifying some ambiguities," Journal of Risk and Uncertainty, Springer, vol. 51(1), pages 1-21, August.
  11. Amitabh Chandra & Jonathan Skinner, 2012. "Technology Growth and Expenditure Growth in Health Care," Journal of Economic Literature, American Economic Association, vol. 50(3), pages 645-680, September.
  12. Parry, Ian W.H. & Laxminarayan, Ramanan & West, Sarah E., 2006. "Fiscal and Externality Rationales for Alcohol Taxes," Discussion Papers dp-06-51, Resources For the Future.
  13. Andersson, Henrik, 2006. "Willingness to Pay for Road Safety and Estimates of the Risk of Death: Evidence from a Swedish Contingent Valuation Study," Working Papers 2006:5, Swedish National Road & Transport Research Institute (VTI).
  14. Hammitt, James & Roman, Henry & Stieb, David & Walsh, Tyra, 2012. "Expert Elicitation of the Value per Statistical Life in an Air Pollution Context," LERNA Working Papers 12.10.367, LERNA, University of Toulouse.
  15. Restrepo, Brandon J. & Rieger, Matthias, 2016. "Trans fat and cardiovascular disease mortality: Evidence from bans in restaurants in New York," Journal of Health Economics, Elsevier, vol. 45(C), pages 176-196.
  16. W. Kip Viscusi, 2014. "The Role of Publication Selection Bias in Estimates of the Value of a Statistical Life," NBER Working Papers 20116, National Bureau of Economic Research, Inc.
  17. Joseph E. Aldy & W. Kip Viscusi, 2007. "Age Differences in the Value of Statistical Life: Revealed Preference Evidence," Review of Environmental Economics and Policy, Association of Environmental and Resource Economists, vol. 1(2), pages 241-260, Summer.
  18. Julien Hugonnier & Florian Pelgrin & Pascal St-Amour, 2010. "A structural analysis of the health expenditures and portfolio choices of retired agents," Swiss Finance Institute Research Paper Series 10-29, Swiss Finance Institute.
  19. Frank Lichtenberg & Gisela Hostenkamp, 2013. "The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence," CESifo Working Paper Series 4516, CESifo Group Munich.
  20. Kochi Ikuho & Taylor Laura O, 2011. "Risk Heterogeneity and the Value of Reducing Fatal Risks: Further Market-Based Evidence," Journal of Benefit-Cost Analysis, De Gruyter, vol. 2(3), pages 1-28, August.
  21. Rheinberger, Christoph M. & Hammitt, James K., 2014. "The welfare value of FDA's mercury-in-fish advisory: A dynamic reanalysis," Journal of Health Economics, Elsevier, vol. 37(C), pages 113-122.
  22. Svensson, Mikael, 2006. "The Value of a Statistical Life in Sweden Estimates from Two Studies using the "Certainty Approach" Calibration," Working Papers 2006:6, Örebro University, School of Business, revised 25 Jul 2007.
  23. Chandra Amitabh & MacEwan Joanna P. & Campinha-Bacote Avrita & Khan Zeba M., 2016. "Returns to Society from Investment in Cancer Research and Development," Forum for Health Economics & Policy, De Gruyter, vol. 19(1), pages 71-86, June.
  24. Thomas J. Kniesner & W. Kip Viscusi & Christopher Woock & James P. Ziliak, 2012. "The Value of a Statistical Life: Evidence from Panel Data," The Review of Economics and Statistics, MIT Press, vol. 94(1), pages 74-87, February.
  25. Gentry, Elissa Philip & Viscusi, W. Kip, 2016. "The fatality and morbidity components of the value of statistical life," Journal of Health Economics, Elsevier, vol. 46(C), pages 90-99.
  26. W. Viscusi & Elissa Gentry, 2015. "The value of a statistical life for transportation regulations: A test of the benefits transfer methodology," Journal of Risk and Uncertainty, Springer, vol. 51(1), pages 53-77, August.
  27. The Untold Standards of Living Story: The GDP value of Twentieth Century Health Improvements in Developed Economies, 2012. "Hickson, Kerry," CAGE Online Working Paper Series 105, Competitive Advantage in the Global Economy (CAGE).
  28. W. Viscusi, 2008. "How to value a life," Journal of Economics and Finance, Springer;Academy of Economics and Finance, vol. 32(4), pages 311-323, October.
  29. Bergstrom, Ted & Sheehan-Connor, Damien & Garratt, Rodney J, 2015. "Saving lives with stem cell transplants," University of California at Santa Barbara, Economics Working Paper Series qt57w7r9s8, Department of Economics, UC Santa Barbara.
  30. James Hammitt, 2013. "Admissible utility functions for health, longevity, and wealth: integrating monetary and life-year measures," Journal of Risk and Uncertainty, Springer, vol. 47(3), pages 311-325, December.
  31. Martin Lauren & Lotspeich Richard, 2014. "A benefit-cost framework for early intervention to prevent sex trading," Journal of Benefit-Cost Analysis, De Gruyter, vol. 5(1), pages 1-45, January.
  32. van Benthem, Arthur, 2015. "What is the optimal speed limit on freeways?," Journal of Public Economics, Elsevier, vol. 124(C), pages 44-62.
  33. Frankovic, Ivan & Kuhn, Michael & Wrzaczek, Stefan, 2016. "Medical care within an OLG economy with realistic demography," ECON WPS - Vienna University of Technology Working Papers in Economic Theory and Policy 02/2016, Vienna University of Technology, Institute for Mathematical Methods in Economics, Research Group Economics (ECON).
  34. James Hammitt & Kevin Haninger, 2010. "Valuing fatal risks to children and adults: Effects of disease, latency, and risk aversion," Journal of Risk and Uncertainty, Springer, vol. 40(1), pages 57-83, February.
  35. Ryan D. Edwards, 2008. "The Cost of Uncertain Life Span," NBER Working Papers 14093, National Bureau of Economic Research, Inc.
  36. Jytte Nielsen & Susan Chilton & Michael Jones-Lee & Hugh Metcalf, 2010. "How would you like your gain in life expectancy to be provided? An experimental approach," Journal of Risk and Uncertainty, Springer, vol. 41(3), pages 195-218, December.
  37. James Hammitt & Tuba Tunçel, 2015. "Preferences for life-expectancy gains: Sooner or later?," Journal of Risk and Uncertainty, Springer, vol. 51(1), pages 79-101, August.
  38. Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
  39. Trudy Cameron & J. DeShazo & Peter Stiffler, 2010. "Demand for health risk reductions: A cross-national comparison between the U.S. and Canada," Journal of Risk and Uncertainty, Springer, vol. 41(3), pages 245-273, December.
  40. Brajer, Victor & Mead, Robert W. & Xiao, Feng, 2008. "Health benefits of tunneling through the Chinese environmental Kuznets curve (EKC)," Ecological Economics, Elsevier, vol. 66(4), pages 674-686, July.
  41. Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
  42. Frank Lichtenberg, 2015. "The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 207-222, April.
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.